Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

@article{Chey2012LinaclotideFI,
  title={Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety},
  author={William D. Chey and Anthony Lembo and Bernard J. Lavins and Steven J. Shiff and Caroline B. Kurtz and Mark G. Currie and James E Macdougall and Xinwei Daniel Jia and James Z. Shao and Donald A Fitch and Mollie J Baird and Harvey A. Schneier and Jeffrey M. Johnston},
  journal={The American Journal of Gastroenterology},
  year={2012},
  volume={107},
  pages={1702-1712}
}
OBJECTIVES:Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients with irritable bowel syndrome with constipation (IBS-C) over 26 weeks.METHODS:This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μg of oral linaclotide once daily for a 26-week treatment period. The primary and the secondary efficacy assessments… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 129 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

A novel role of cyclic GMP in colonic sensory neurotransmission in healthy and TNBS - treated mice

  • J Castro, C Martin, PA Hughes
  • Gastroenterology
  • 2011

Guidance for industry : irritable bowel syndrome – clinical evaluation of drugs for treatment

  • SJ Lewis, KW Heaton
  • Guidance for Industry Patient - Reported Outcome…
  • 2009

Similar Papers

Loading similar papers…